Senior Leadership The Cancer Center requests support (16.2 calendar months, 1.35 FTE, $334,153) for an experienced and enhanced Senior Leadership team that includes Shelton Earp, MD (Director) and eight Associate Directors, including: Albert Baldwin, PhD (Basic Sciences), William Marzluff, PhD (Basic Science Cores), Richard Goldberg, MD (Clinical Research);Lisa Carey, MD (Clinical Science), Ned Sharpless MD (Translational Science);Tom Shea (Clinical Outreach), Andy Olshan (Population Sciences), and Michael O'Malley, PhD (Administration and Planning). The team has been strengthened by the addition of Drs. Carey, Sharpless, Shea, and Olshan. These new leaders join a stable group, almost all of whom have been with the Center for more than 15 years. The Director and Senior Leaders interact frequently. In addition to multiple individual interactions, the Senior Leadership team meets weekly with the Director. Senior Leaders are members of the Center's Program Planning Committee, which meets monthly. They are also active participants in their respective research programs and interact scientifically with the Program Leaders and program members. They interact with the Center's visitors, meeting individually, for example, with most of the seminar speakers to discuss the Center's development. Senior (and Program) Leaders are intimately involved in recruiting, serving as chairs or members of all the search committees. They contribute significantly to the Center's strategic planning process and the overall planning and evaluation effort.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016086-38
Application #
8594110
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2013-12-01
Budget End
2014-11-30
Support Year
38
Fiscal Year
2014
Total Cost
$271,532
Indirect Cost
$66,182
Name
University of North Carolina Chapel Hill
Department
Type
DUNS #
608195277
City
Chapel Hill
State
NC
Country
United States
Zip Code
27599
Wang, Jeremy R; Holt, James; McMillan, Leonard et al. (2018) FMLRC: Hybrid long read error correction using an FM-index. BMC Bioinformatics 19:50
Lee, Janie M; Abraham, Linn; Lam, Diana L et al. (2018) Cumulative Risk Distribution for Interval Invasive Second Breast Cancers After Negative Surveillance Mammography. J Clin Oncol 36:2070-2077
Shen, Hui; Shih, Juliann; Hollern, Daniel P et al. (2018) Integrated Molecular Characterization of Testicular Germ Cell Tumors. Cell Rep 23:3392-3406
Shao, Wenwei; Chen, Xiaojing; Samulski, Richard J et al. (2018) Inhibition of antigen presentation during AAV gene therapy using virus peptides. Hum Mol Genet 27:601-613
Gao, Yanzhe; Kardos, Jordan; Yang, Yang et al. (2018) The Cancer/Testes (CT) Antigen HORMAD1 promotes Homologous Recombinational DNA Repair and Radioresistance in Lung adenocarcinoma cells. Sci Rep 8:15304
Schaefer, Kristina N; Bonello, Teresa T; Zhang, Shiping et al. (2018) Supramolecular assembly of the beta-catenin destruction complex and the effect of Wnt signaling on its localization, molecular size, and activity in vivo. PLoS Genet 14:e1007339
Zuze, Takondwa; Painschab, Matthew S; Seguin, Ryan et al. (2018) Plasmablastic lymphoma in Malawi. Infect Agent Cancer 13:22
Zhang, Zhi-Min; Lu, Rui; Wang, Pengcheng et al. (2018) Structural basis for DNMT3A-mediated de novo DNA methylation. Nature 554:387-391
Desai, Neelam V; Torous, Vanda; Parker, Joel et al. (2018) Intrinsic molecular subtypes of breast cancers categorized as HER2-positive using an alternative chromosome 17 probe assay. Breast Cancer Res 20:75
Thomas, Nancy E; Edmiston, Sharon N; Orlow, Irene et al. (2018) Inherited Genetic Variants Associated with Melanoma BRAF/NRAS Subtypes. J Invest Dermatol 138:2398-2404

Showing the most recent 10 out of 1525 publications